Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

Document Type


Publication Date


Notes/Citation Information

Published in Biotechnology Reports, v. 15, p. 24-26.

© 2017 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).

Digital Object Identifier (DOI)


Funding Information

A portion of this work was supported by the National Institute of Dental and Craniofacial Research Small Business Innovation Research grant # 1R43 DE024032-01(Soligenix, Inc).